Regulation 2
Regulation 2
concern because alterations are passed to offspring, only 29 countries have enacted it into law. For more on China’s new
human gene-editing rules see
with the risk of perpetuating unexpected and undesired It is almost 20 years since scientists announced the https://www.bbc.co.uk/news/
changes through generations. It is impossible for our mapping of the human genome. Now they are editing science-environment-64857311
For more on the Third
unborn descendants to give consent. it, and the promise of a truly personalised medicine, International Human Genome
Loopholes and ambiguities in regulation need to tailored to an individual’s genetic makeup, is becoming Editing Summit see https://
royalsociety.org/science-events-
be closed urgently to enable scientists to be held to reality. The first CRISPR-based technology, for sickle cell and-lectures/2023/03/2023-
account. In China, He’s prosecution was based on disease, is expected to soon be approved by US regulators. human-genome-editing-
summit/
practising medicine without a licence, rather than Such advances have the potential to bring enormous
For more on existing guidelines
specifically based on a provision governing assisted benefits for humankind, but also bring unique social and for gene editing see https://nap.
reproduction or genome editing. China has since ethical challenges. Resolving these challenges will involve nationalacademies.org/
catalog/25665/heritable-
instituted new regulations, widely seen as a response to ongoing conversations within and outside the scientific human-genome-editing and
the He case, but they have been criticised in press reports community. To protect legitimate genetic research—to https://www.who.int/
publications/i/
for not doing enough to cover private companies. close loopholes in regulations and establish a global item/9789240030060
Wording of legislation needs to be explicit and clear. consensus on oversight and regulation—will require For more on the Oviedo
Convention see https://rm.coe.
In the USA, use of funds by the FDA for the purpose of governance that is as dynamic as the science. n The Lancet int/strategic-action-plan-final-
accepting and reviewing any application to begin a e/1680a2c5d2